This Article Full Text (PDF) All Versions of this Article: 1087057107312778v1 13/2/101    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Szekeres, P. G. Articles by Karran, E. H. Search for Related Content PubMed PubMed Citation Articles by Szekeres, P. G. Articles by Karran, E. H. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Medline Plus Health Information Alzheimer's Disease Social Bookmarking                         What's this?

Development of Homogeneous 384-Well High-Throughput Screening Assays for Aβ1-40 and Aβ1-42 Using AlphaScreen^TM Technology

Eli Lilly and Co. Ltd., Lilly Research Centre, Windlesham, Surrey, UK, szekeresp{at}lilly.com

Kaitlin Leong

Eli Lilly and Co. Ltd., Lilly Research Centre, Windlesham, Surrey, UK

Theresa A. Day

Lilly Corporate Center, Indianapolis, Indiana

Ann E. Kingston

Lilly Corporate Center, Indianapolis, Indiana

Eric H. Karran

Eli Lilly and Co. Ltd., Lilly Research Centre, Windlesham, Surrey, UK

Amyloid beta (Aβ) peptides are the major constituent of amyloid plaques, one of the hallmark pathologies of Alzheimer's disease. Accurate and precise quantitation of these peptides in biological fluids is a critical component of Alzheimer's disease research. The current most established assay for analysis of Aβ peptides in preclinical research is enzyme-linked immunosorbent assay (ELISA), which, although sensitive and of proven utility, is a multistep, labor-intensive assay that is difficult to automate completely. To overcome these limitations, the authors have developed and optimized simple, sensitive, homogeneous 384-well assays for Aβ1-42 and Aβ1-40 using AlphaScreen^TM technology. The assays are capable of detecting Aβ peptides at concentrations <2 pg/mL and, using a final assay volume of 20 µL, routinely generate Z' values >0.85. The AlphaScreen^TM format has the following key advantages: substantially less hands-on time to run, easier to automate, higher throughput, and less expensive to run than the traditional ELISA. The results presented here show that AlphaScreen^TM technology permits robust, efficient, and cost-effective quantitation of Aβ peptides. (Journal of Biomolecular Screening 2008:101-111)

Key Words: AlphaScreen^TM • amyloid beta peptides • Alzheimer's disease

This version was published on February 1, 2008

Journal of Biomolecular Screening, Vol. 13, No. 2, 101-111 (2008)
DOI: 10.1177/1087057107312778


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Harndahl, S. Justesen, K. Lamberth, G. Roder, M. Nielsen, and S. Buus Peptide Binding to HLA Class I Molecules: Homogenous, High-Throughput Screening, and Affinity Assays J Biomol Screen, February 1, 2009; 14(2): 173 - 180. [Abstract] [PDF]